Treatment of cystic fibrosis

On 14/09/2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 474. The active ingredient is Alpha-1 proteinase inhibitor (inhalation use) for treatment of cystic fibrosis.